Main points of investment
Innovative platform for assisted reproductive gene detection solutions. Baycom Medical, as a leader in NGS market segment-reproductive field, is committed to the research and development and clinical application of high-throughput sequencing technology in the field of reproductive health, compared with other PGT-A products based on fluorescence in situ hybridization (FISH) and quantitative polymerase chain reaction (qPCR) technology. The company's PGT-A kit, which can screen embryos for aneuploidy (a chromosomal disease often associated with failed IVF implantation) before implantation, is the first and only third-generation IVF genetic test kit approved by the SFDA. The company is developing two other preimplantation genetic testing (PGT) products, PGT-M and PGT-SR kits, which, together with PGT-A kits, will form a complete family of testing kits in the PGT field.
The above two kits are expected to be registered and approved by the State Drug Administration in 2022 and 2024 respectively, which will further consolidate the company's dominant position in the market for gene testing kits for third-generation test-tube babies in China.
The awareness and acceptance of PGT are increasing. The huge population base and the PGT penetration rate, which is much lower than in the United States, suggest that the market has great potential for growth. With the company's leading position in the PGT field, the company will be able to serve a larger market for reproductive genetics medical devices through strategic positioning in the future. Driven by the clinical-oriented R & D model, the company has a strong R & D capability to develop innovative reproductive genetics solutions to address the unmet clinical needs of the current market. these solutions are tailored to overcome the special challenges of the Chinese patient community.
According to the specific individual needs, the company provides one-stop customized comprehensive solutions for assisted reproductive hospitals and reproductive clinics, including not only consumable testing kits and hardware equipment and instruments. it also includes integrated services such as guidance and advice on laboratory design, operation and management, pre-sales and after-sales technical support. Help them build and further improve their reproductive gene detection, analysis and counseling capabilities from scratch. The company's comprehensive solutions can better serve patients with reproductive diseases in China in an unprecedented way.
Risk hint: the industry is still in an emerging industry, the policy is unstable and the future is uncertain; the company invests heavily in R & D and will continue to invest high in R & D, and the follow-up funds face greater pressure; most products have not yet been approved, there is a risk that the regulatory approval process is time-consuming and uncertain.